Crossbow Therapeutics, Inc., a biotechnology company focused on advancing T-Bolt™ therapies, a novel class of antibody therapeutics that mimic T-cell receptors (TCR-mimetics), today announced the nomination of its first development candidate, CBX-250, a first-in-class, potent, and specific T-cell engager (TCE) for the treatment of myeloid leukemia.

Crossbow Therapeutics，Inc.，一家专注于推进T-Bolt™疗法的生物技术公司，这是一种模拟T细胞受体（TCR模拟物）的新型抗体疗法，今天宣布提名其第一个开发候选人CBX-250，一种用于治疗髓系白血病的一流，有效和特异性T细胞接受者（TCE）。

Researchers from Crossbow and The University of Texas MD Anderson Cancer Center will present an abstract describing preclinical characteristics of CBX-250 at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, Calif., which takes place April 5-10, 2024. The oral presentation will provide an overview of the preclinical characteristics of CBX-250, which targets a cathepsin G (CTSG) peptide-human leukocyte antigen (pHLA) complex.

Crossbow和德克萨斯大学MD安德森癌症中心的研究人员将在2024年4月5日至10日于加利福尼亚州圣地亚哥举行的美国癌症研究协会（AACR）2024年年会上提交一份摘要，描述CBX-250的临床前特征。口头介绍将概述CBX-250的临床前特征，CBX-250靶向组织蛋白酶G（CTSG）肽-人白细胞抗原（pHLA）复合物。

The complex is abundantly expressed on leukemic cells, but not on normal cells, allowing CBX-250 to target cancer cells efficiently while sparing normal myeloid cells. CBX-250 may offer an enhanced therapeutic window compared with TCEs that have shown limited clinical benefit in the treatment of myeloid malignancies, due to the lack of tumor-specific surface antigens.

该复合物在白血病细胞上大量表达，但在正常细胞上不表达，从而使CBX-250能够有效靶向癌细胞，同时保留正常的骨髓细胞。由于缺乏肿瘤特异性表面抗原，与在治疗骨髓恶性肿瘤方面显示出有限临床益处的TCE相比，CBX-250可能提供增强的治疗窗口。

“Nominating CBX-250 as a development candidate validates our initial scientific hypothesis, and it brings us a step closer to entering the clinic and ultimately helping to cure cancer,” said Briggs Morri.

布里格斯·莫里（Briggs Morri）说：“提名CBX-250作为开发候选人，验证了我们最初的科学假设，这使我们离进入诊所并最终帮助治愈癌症更近了一步。”